JP2023523373A - アルツハイマー病に関連する激越を治療する方法 - Google Patents

アルツハイマー病に関連する激越を治療する方法 Download PDF

Info

Publication number
JP2023523373A
JP2023523373A JP2023509465A JP2023509465A JP2023523373A JP 2023523373 A JP2023523373 A JP 2023523373A JP 2023509465 A JP2023509465 A JP 2023509465A JP 2023509465 A JP2023509465 A JP 2023509465A JP 2023523373 A JP2023523373 A JP 2023523373A
Authority
JP
Japan
Prior art keywords
patient
cmai
score
administering step
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023509465A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023523373A5 (enExample
Inventor
デュベ，サンジャイ
Original Assignee
アバニア ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アバニア ファーマシューティカルズ， インコーポレイテッド filed Critical アバニア ファーマシューティカルズ， インコーポレイテッド
Publication of JP2023523373A publication Critical patent/JP2023523373A/ja
Publication of JP2023523373A5 publication Critical patent/JP2023523373A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023509465A 2020-04-27 2021-04-26 アルツハイマー病に関連する激越を治療する方法 Pending JP2023523373A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063016270P 2020-04-27 2020-04-27
US63/016,270 2020-04-27
PCT/US2021/029246 WO2021222145A1 (en) 2020-04-27 2021-04-26 Methomethods of treating agitation associated with alzheimer's disease

Publications (2)

Publication Number Publication Date
JP2023523373A true JP2023523373A (ja) 2023-06-02
JP2023523373A5 JP2023523373A5 (enExample) 2024-04-19

Family

ID=75914613

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023509465A Pending JP2023523373A (ja) 2020-04-27 2021-04-26 アルツハイマー病に関連する激越を治療する方法

Country Status (13)

Country Link
US (1) US20230270738A1 (enExample)
EP (1) EP4142729A1 (enExample)
JP (1) JP2023523373A (enExample)
KR (1) KR20230016636A (enExample)
CN (1) CN115734787A (enExample)
AU (1) AU2021263354A1 (enExample)
BR (1) BR112022021535A2 (enExample)
CA (1) CA3176234A1 (enExample)
IL (1) IL296977A (enExample)
MX (1) MX2022013427A (enExample)
PH (1) PH12022552764A1 (enExample)
TW (1) TW202203922A (enExample)
WO (1) WO2021222145A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2792662T3 (da) 2007-05-01 2016-07-25 Concert Pharmaceuticals Inc Morphinanforbindelser
CN115322150B (zh) * 2021-05-11 2024-05-28 深圳信立泰药业股份有限公司 氘代右美沙芬氢溴酸盐的固体及其制备方法和医药用途
KR20240110812A (ko) * 2021-10-27 2024-07-16 아바니르 파마슈티컬스, 인코포레이티드 알츠하이머병과 관련된 불안을 치료하는 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017531033A (ja) * 2014-09-14 2017-10-19 アヴェニール ファーマシューティカルズ， インコーポレイテッド 認知症における激越の処置のためのデキストロメトルファン化合物およびキニジンを含む医薬組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206248A (en) 1992-03-27 1993-04-27 Smith Richard A Method for reducing emotional lability
US20160143901A1 (en) * 2006-02-03 2016-05-26 Avanir Pharmaceuticals, Inc. Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of agitation in dementia
MX370608B (es) 2007-05-01 2019-12-18 Concert Pharmaceuticals Inc Compuestos de morfinano.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017531033A (ja) * 2014-09-14 2017-10-19 アヴェニール ファーマシューティカルズ， インコーポレイテッド 認知症における激越の処置のためのデキストロメトルファン化合物およびキニジンを含む医薬組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
大塚製薬株式会社: "アルツハイマー型認知症に伴う行動障害（アジテーション）を対象とした「ＡＶＰ−７８６」のフェーズ３試験", ニュースリリース, JPN6025011440, 25 March 2019 (2019-03-25), ISSN: 0005688108 *
服部英幸 ほか, 老年精神医学雑誌, vol. 第25巻第2号, JPN6025011441, 2014, pages 185 - 192, ISSN: 0005688109 *

Also Published As

Publication number Publication date
EP4142729A1 (en) 2023-03-08
IL296977A (en) 2022-12-01
WO2021222145A1 (en) 2021-11-04
BR112022021535A2 (pt) 2023-01-24
US20230270738A1 (en) 2023-08-31
KR20230016636A (ko) 2023-02-02
TW202203922A (zh) 2022-02-01
WO2021222145A8 (en) 2021-12-30
PH12022552764A1 (en) 2024-03-25
MX2022013427A (es) 2023-01-19
AU2021263354A1 (en) 2022-10-27
CN115734787A (zh) 2023-03-03
CA3176234A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
KR102316933B1 (ko) 헌팅턴병 치료를 위한 프리도피딘의 용도
US20210338692A1 (en) A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
US11090297B2 (en) Pridopidine for treating huntington's disease
JP2026050474A (ja) Ｎｍｄａ拮抗薬の副作用の低減
JP2008513491A (ja) 自閉症、強迫神経症、および衝動性の治療のためのメマンチン（ナメンダ）の使用
KR20250005175A (ko) 양극성 장애의 치료를 위한 5-meo-dtm
KR20240006026A (ko) 주요 우울 장애 및 산후 우울증을 치료하는 데 사용하기 위한 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드
KR20240148425A (ko) Cns-관련 장애의 치료를 위한 신경활성 스테로이드
US9603812B2 (en) Treatment of autistic spectrum disorder
US20250000881A1 (en) Treatment of treatment resistant depression with psilocybin
JP2020530032A (ja) ３−メチルメトカチノンの使用
KR20230016636A (ko) 알츠하이머병과 관련된 불안을 치료하는 방법
KR20250048143A (ko) 코카인 사용 감소 또는 코카인 사용 재발 예방에 있어서 마보글루란트의 용도
WO2025128594A1 (en) Methods of treating generalized anxiety disorder
CN113825510A (zh) 使用氘化右美沙芬和奎尼丁治疗精神分裂症的阴性症状的方法
JP2024540104A (ja) アルツハイマー病に関連する激越を治療する方法
KR20250019704A (ko) 우울증 장애의 치료에 사용하기 위한 온파스프로딜의 피하 투여 및 투약 방법
EP2983652B1 (en) Treatment of autistic spectrum disorder
JP2002544156A (ja) 早期射精改善のための投薬計画およびキット
HK40089955A (en) Methods of treating agitation associated with alzheimer's disease
CN118510513A (zh) 治疗与阿尔茨海默氏病相关的激越的方法
Dreyer Pharmacology for nurses and other health workers
HK40060751A (en) Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine
PRESCRIBED Change for
Diaz-Marsa et al. THE INTERNATIONAL JOURNAL OF NEUROPS YC HI ATR IC MEDICINE

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240408

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240408

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250321

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250325

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250916